SCHEMBL75124

SCHEMBL75124

O=C(O)Cc1noc2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.62
SMN1; SMN2 Q16637 7/20 0.58
RAB9A P51151 5/20 0.57
NPC1 O15118 4/20 0.57
LMNA P02545 3/20 0.57
KDM4E B2RXH2 3/20 0.57
ALDH1A1 P00352 2/20 0.57
GAA P10253 2/20 0.57
TP53 P04637 1/20 0.56
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA3 P07451 1/20 0.56
CA4 P22748 1/20 0.56
CA6 P23280 1/20 0.56
MAOB P27338 1/20 0.56
CA5A P35218 1/20 0.56
CA7 P43166 1/20 0.56
CA9 Q16790 1/20 0.56
CA13 Q8N1Q1 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Alcohol SCHEMBL11211940 0.97 MAPT (0.63) MAPTSMN1; SMN2RAB9ANPC1LMNA
Toluene SCHEMBL11204804 0.92 MAPT (0.67) MAPTSMN1; SMN2RAB9ANPC1LMNA
Benzyl Alcohol SCHEMBL11208104 0.91 MAPT (0.54) MAPTSMN1; SMN2RAB9ANPC1LMNA
SCHEMBL4907408 0.91 LMNA (0.55) MAPTSMN1; SMN2RAB9ANPC1LMNA
SCHEMBL5697386 0.87 MAPT (0.53) MAPTSMN1; SMN2RAB9ANPC1LMNA
SCHEMBL10916558 0.86 SMN1; SMN2 (0.57) MAPTSMN1; SMN2RAB9ANPC1LMNA
SCHEMBL2793131 0.84 LMNA (0.58) MAPTSMN1; SMN2RAB9ANPC1LMNA
SCHEMBL10242664 0.84 SMN1; SMN2 (0.59) MAPTSMN1; SMN2RAB9ANPC1LMNA
SCHEMBL28603039 0.83 RAB9A (0.64) MAPTSMN1; SMN2RAB9ANPC1LMNA
SCHEMBL6997107 0.83 LMNA (0.53) MAPTSMN1; SMN2RAB9ANPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1728786-B1 ONE-POT PROCESS FOR PRODUCING 1,2-BENZISOXAZOLE-3-METHANESULFONAMIDE SUMITOMO DAINIPPON PHARMA CO LTD (JP) 2016-01-13 EP claimed
CN-1934096-B Single-pot preparation method of 1, 2-benzisoxazole-3-methyl sulfonamide DAINIPPON SUMITOMO PHARMA CO 2012-04-18 CN claimed
CN-101263128-B Sulfonation method of 1, 2-benzisoxazole-3-acetic acid DAINIPPON SUMITOMO PHARMA CO 2011-02-16 CN claimed
CN-101263128-A Sulfonation method of 1, 2-benzisoxazole-3-acetic acid DAINIPPON SUMITOMO PHARMA CO (JP) 2008-09-10 CN claimed
EP-1935888-A1 METHOD FOR SULFONATING 1,2-BENZISOXAZOLE-3-ACETIC ACID Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-06-25 EP claimed
US-7268234-B2 Method for sulfonation of 1,2-benzisoxazole-3-acetic acid DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-09-11 US claimed
US-7262304-B2 One-pot process for the preparation of 1,2-benzisoxazole-3-methanesulfonamide DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-08-28 US claimed
US-20070066830-A1 METHOD FOR SULFONATION OF 1,2-BENZISOXAZOLE-3-ACETIC ACID DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-03-22 US claimed
CN-1934096-A One-pot process for the preparation of 1,2-benzisoxazole-3-methanesulfonamide DAINIPPON SUMITOMO PHARMA CO (JP) 2007-03-21 CN claimed
US-20060287535-A1 Process for the manufacture of 1,2-benzisoxazole-3-methanesulphonamide WOCKHARDT LIMITED 2006-12-21 US claimed
EP-1728786-A1 ONE-POT PROCESS FOR PRODUCING 1,2-BENZISOXAZOLE-3-METHANESULFONAMIDE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-12-06 EP claimed
US-20060229454-A1 One-pot process for the preparation of 1,2-benzisoxazole-3-methanesulfonamide Sumitomo Pharma Co., Ltd. (JP) 2006-10-12 US claimed
US-7081539-B2 One-pot process for the preparation of 1,2-benzisoxazole-3-methanesulfonamide DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2006-07-25 US claimed
US-20060084814-A1 Process for the preparation of zonisamide GLENMARK PHARMACEUTICALS LIMITED (IN) 2006-04-20 US claimed
US-20050215796-A1 One-pot process for the preparation of 1,2-benzisoxazole-3-methanesulfonamide Sumitomo Pharma Co., Ltd. (JP) 2005-09-29 US claimed
US-20040049053-A1 Process for the prepartion of 1,2-benzisoxazole-3-acetic acid MENDELOVICI MARIOARA (IL) 2004-03-11 US claimed
US-6677458-B2 REACTING 4-HYDROXY-COUMARIN WITH HYDROXYL-AMINE IN THE PRESENCE OF A BASE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2004-01-13 US claimed
US-20020183525-A1 Process for the preparation of 1,2-benzisoxazole-3-acetic acid TEVA PHARMACEUTICALS USA, INC. 2002-12-05 US claimed
US-12534442-B2 Benzisoxazole derivative Sumitomo Pharma Co., Ltd. (JP) 2026-01-27 US disclosed
EP-0063799-A2 1-(3-(6-fluoro-1,2-benzisoxasol-3-yl)propyl)-4-hydroxy-4-phenylpiperidines, a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1982-11-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084814-A1 Process for the preparation of zonisamide CYP3A43, CYP3A4, CYP3A5 MAPT 2606/4885SMN1; SMN2 3439/4885RAB9A 2154/4885
US-20040049053-A1 Process for the prepartion of 1,2-benzisoxazole-3-acetic acid HAO2, CYP4X1, CYP2S1 MAPT 4726/4885SMN1; SMN2 3728/4885RAB9A 4611/4885
US-20020183525-A1 Process for the preparation of 1,2-benzisoxazole-3-acetic acid HAO2, CYP2S1, CYP4X1 MAPT 4636/4885SMN1; SMN2 3094/4885RAB9A 4685/4885
US-20060287535-A1 Process for the manufacture of 1,2-benzisoxazole-3-methanesulphonamide GABRE, CA3, GABRA1 MAPT 1471/4885SMN1; SMN2 958/4885RAB9A 472/4885
US-12534442-B2 Benzisoxazole derivative GABRA6, SLC6A1, GABRA1 MAPT 2827/4885SMN1; SMN2 1568/4885RAB9A 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.